NEVVI Medicare utilization intelligence

← back

RAMADOSS, UMASANKARMD NPI 1962499806 Clinician

Medical Oncology · COLUMBIA, MO

Specialty Medical Oncology — from billed Medicare claims
In practice about 34 years since medical school (class of 1992, self-reported to CMS)
Location COLUMBIA, MO · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 71 codes billed · 250,503 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
MISSOURI CANCER ASSOCIATES LLC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-02

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J0185 Injection, aprepitant, 1 mg
J9299 Injection, nivolumab, 1 mg
J9025 Injection, azacitidine, 1 mg
J0897 Injection, denosumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9267 Injection, paclitaxel, 1 mg
J1439 Injection, ferric carboxymaltose, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J9173 Injection, durvalumab, 10 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J1930 Injection, lanreotide, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J0640 Injection, leucovorin calcium, per 50 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J9190 Injection, fluorouracil, 500 mg
J9395 Injection, fulvestrant, 25 mg
96372 Injection of drug or substance under skin or into muscle
96375 Injection of additional new drug or substance into vein
J9045 Injection, carboplatin, 50 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
71260 Ct scan of chest with contrast
J1200 Injection, diphenhydramine hcl, up to 50 mg
74177 Ct scan of abdomen and pelvis with contrast
J3490 Unclassified drugs
96415 Administration of chemotherapy into vein, each additional hour
J2250 Injection, midazolam hydrochloride, per 1 mg
J7030 Infusion, normal saline solution , 1000 cc
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96361 Infusion into a vein for hydration, each additional hour
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
96360 Infusion into a vein for hydration, 31-60 minutes
96521 Refilling and maintenance of portable pump
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
71250 Ct scan of chest without contrast
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96374 Injection of drug or substance into vein
96523 Irrigation of implanted venous access drug delivery device
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
74176 Ct scan of abdomen and pelvis without contrast
99195 Drawing of blood for a medical problem
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
38222 Biopsy and aspiration of bone marrow sample for diagnosis
74178 Ct scan of abdomen and pelvis before and after contrast
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.